Czer L S C, Goland S, Soukiasian H J, Gallagher S, De Robertis M A, Mirocha J, Siegel R J, Kass R M, Trento A
Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, California 90048, USA.
Transplant Proc. 2013 Jan-Feb;45(1):364-8. doi: 10.1016/j.transproceed.2012.04.032. Epub 2012 Sep 19.
The decision to perform aortic valve replacement (AVR) or heart transplantation (HTx) for aortic stenosis (AS) with severe left ventricular dysfunction is difficult and may be affected by prior myocardial infarction (MI) and coronary artery disease (CAD).
Patients who underwent AVR from 1988 to 2001 with left ventricular ejection fraction (LVEF) <30% and severe AS (aortic valve area [AVA] < 1.0 cm(2); n = 51) were assessed for operative mortality, late survival, and predictors of outcome, and were compared with HTx. Subsequently, 131 patients with LVEF ≤ 35% who underwent AVR for critical AS (AVA < 0.8 cm(2)) were evaluated.
In the first 51 patients, 3-year survival was 100% ± 0% with no CAD, and 45% ± 10% with CAD (P < .05); 3-year survival was 88% ± 12% with no bypass, 73% ± 12% with one to two grafts, and 18% ± 11% with three grafts (P < .01). Survival with HTx was 78% at 3 years. In the subsequent analysis of 131 patients, 90-day survivors were followed for a mean 4.6 ± 3.5 years. Advanced age (P = .001) was the only predictor of long-term mortality. LVEF improved from 28.5% ± 5.2% before AVR to 45.4% ± 13.2% at 1-month postoperatively (P < .0001). New York Heart Association (NYHA) class III/IV decreased from 94.2% pre-AVR to 12.8% at 1 year (P < .0001). Predictors of LVEF recovery were no previous MI (P = .007) and higher AS gradient (P = .03).
In severe AS and LVEF <30% with no concomitant CAD or with CAD requiring one to two bypass grafts, AVR has a survival equal to or exceeding that of HTx. In patients with CAD requiring more than two bypass grafts, survival is significantly reduced, and HTx can be considered.
对于患有严重左心室功能障碍的主动脉瓣狭窄(AS)患者,决定进行主动脉瓣置换术(AVR)还是心脏移植(HTx)是困难的,并且可能受到既往心肌梗死(MI)和冠状动脉疾病(CAD)的影响。
对1988年至2001年间接受AVR且左心室射血分数(LVEF)<30%以及严重AS(主动脉瓣面积[AVA]<1.0 cm²;n = 51)的患者进行手术死亡率、晚期生存率及预后预测因素评估,并与HTx患者进行比较。随后,对131例因严重AS(AVA<0.8 cm²)接受AVR且LVEF≤35%的患者进行评估。
在最初的51例患者中,无CAD者3年生存率为100%±0%,有CAD者为45%±10%(P<.05);未行搭桥者3年生存率为88%±12%,行一至两支移植血管者为73%±12%,行三支移植血管者为18%±11%(P<.01)。HTx患者3年生存率为78%。在随后对131例患者的分析中,对90天存活者平均随访4.6±3.5年。高龄(P =.001)是长期死亡率的唯一预测因素。LVEF从AVR术前的28.5%±5.2%提高到术后1个月时的45.4%±13.2%(P<.0001)。纽约心脏协会(NYHA)III/IV级从AVR术前的94.2%降至术后1年时的12.8%(P<.0001)。LVEF恢复的预测因素为既往无MI(P =.007)和较高的AS压差(P =.03)。
对于严重AS且LVEF<30%且无合并CAD或合并CAD但仅需一至两支搭桥移植血管的患者,AVR后的生存率等于或超过HTx。对于需要两支以上搭桥移植血管的CAD患者,生存率显著降低,可考虑HTx。